FATE Market Cap History
Below is a table of the FATE market cap history going back to 11/11/2013:

Date FATE Market Cap
11/11/201394.66M
3/13/2014179.22M
5/9/2014140.52M
8/7/2014119.47M
11/11/201481.25M
3/12/2015104.84M
5/5/2015102.59M
8/3/2015197.99M
11/2/2015133.53M
3/2/201649.06M
5/6/201649.36M
8/5/201660.97M
11/4/201666.59M
3/13/2017209.00M
5/12/2017166.02M
8/14/2017127.97M
10/31/2017198.84M
3/2/2018700.25M
5/7/2018556.07M
8/3/2018522.44M
10/30/2018781.32M
3/1/20191.08B
5/6/20191.17B
8/5/20191.26B
11/4/20191.16B
2/28/20202.22B
5/7/20202.16B
8/3/20202.88B

Also see: FATE Shares Outstanding History
and FATE YTD Return
FATE Historical Market Cap:
+66.16% CAGR
FATE Historical Market Cap: +66.16% CAGR

Mouse over chart for data details
11/11/2013 ...8/3/2020
Fate Therapeutics is a biopharmaceutical company. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC)-derived cellular immunotherapy pipeline include: FT500, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf NK cell cancer immunotherapy. Co.'s other iPSC-derived cell product candidates include: FT301, an off-the-shelf, immuno-regulatory cell product candidate derived from a clonal master iPSC line. Co.'s allogeneic cellular immunotherapy pipeline include: ProTmune™, an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft. We show 28 historical shares outstanding datapoints in our FATE shares outstanding history coverage, used to compute FATE market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing FATE market cap history over the course of time is important for investors interested in comparing FATE's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of FATE versus a peer is one thing; comparing FATE market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like FATE can fluctuate over the course of history. With this page we aim to empower investors researching FATE by allowing them to research the FATE market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for FATE:
FATE SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Fate Therapeutics (FATE) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

FCRE Market Cap History
FCSC Market Cap History
FGEN Market Cap History
FLDM Market Cap History
FLGT Market Cap History
FLKS Market Cap History
FLXN Market Cap History
FMI Market Cap History
FOLD Market Cap History
FONR Market Cap History
More Healthcare companies »

 

FATE Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2020, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.